The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) is a huge mover today! The stock increased 2.65% or $0.2 during the last trading session, reaching $7.76. About 67,939 shares traded. RedHill Biopharma Ltd. (NASDAQ:RDHL) has declined 29.03% since June 13, 2017 and is downtrending. It has underperformed by 41.60% the S&P500. Some Historical RDHL News: ; 08/05/2018 – REDHILL BIOPHARMA LTD QTRLY LOSS PER ORDINARY SHARE $0.05; 09/04/2018 – RedHill: Top-line Results From Confirmatory Phase III Study With TALICIA 1 for H. Pylori Infection Expected in 2H; 07/05/2018 – RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s Disease; 07/05/2018 – REDHILL BIOPHARMA – TOP-LINE RESULTS FROM PHASE lll STUDY WITH RHB-104 FOR CROHN’S DISEASE EXPECTED TO BE ANNOUNCED IN APPROXIMATELY THREE MONTHS; 16/03/2018 – DoD – US Navy: Navy Informs Community at Red Hill Workshop; 09/04/2018 – RedHill Sees Continued Qtrly Revenue Growth; 26/03/2018 – RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA® for IBS-D; 30/05/2018 – RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018; 09/04/2018 – RedHill Biopharma Provides Semi-Annual Business Update; 09/04/2018 – REDHILL SEES QUARTER OVER QUARTER NET REV. GROWTHThe move comes after 7 months positive chart setup for the $163.89M company. It was reported on Jun, 13 by Barchart.com. We have $8.23 PT which if reached, will make NASDAQ:RDHL worth $9.83M more.
Cancer Genetics Inc (NASDAQ:CGIX) had a decrease of 6.71% in short interest. CGIX’s SI was 368,500 shares in June as released by FINRA. Its down 6.71% from 395,000 shares previously. With 162,500 avg volume, 2 days are for Cancer Genetics Inc (NASDAQ:CGIX)’s short sellers to cover CGIX’s short positions. The SI to Cancer Genetics Inc’s float is 2.38%. The stock decreased 2.03% or $0.0227 during the last trading session, reaching $1.0973. About 52,416 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has declined 74.25% since June 13, 2017 and is downtrending. It has underperformed by 86.82% the S&P500. Some Historical CGIX News: ; 18/04/2018 – Pomerantz Law Firm Announces the Filing of a Class Action against Cancer Genetics, Inc. and Certain Officers — CGIX; 20/04/2018 – DJ Cancer Genetics Inc, Inst Holders, 1Q 2018 (CGIX); 15/05/2018 – Cancer Genetics 1Q Loss $4.46M; 18/04/2018 – Pomerantz Law Firm Announces the Filing of a Class Action against Cancer Genetics, Inc. and Certain Officers – CGIX; 15/05/2018 – Cancer Genetics 1Q Rev $7.67M; 06/04/2018 – Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cancer Genetics, Inc. (CGIX); 19/04/2018 – Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Cancer Genetics, Inc. (CGIX); 16/04/2018 – Cancer Genetics’ Unique Tissue of Origin Test (TOO®) Receives Special FDA 510(k) Clearance; 06/04/2018 – Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Cancer Genetics, Inc. (CGIX) and Encourages Investors to Contact the Firm; 15/05/2018 – Cancer Genetics 1Q Loss/Shr 16c
More notable recent RedHill Biopharma Ltd. (NASDAQ:RDHL) news were published by: Bizjournals.com which released: “FDA grants Cary’s Chiesi new designation” on June 13, 2018, also Nasdaq.com with their article: “Factors of Influence in 2018, Key Indicators and Opportunity within BiondVax Pharmaceuticals, MercadoLibre, 1-800 …” published on June 05, 2018, Nasdaq.com published: “RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018” on May 30, 2018. More interesting news about RedHill Biopharma Ltd. (NASDAQ:RDHL) were released by: Streetinsider.com and their article: “RedHill Biopharma (RDHL) Receives New US Patent for its Experimental Ebola Therapy” published on May 29, 2018 as well as Benzinga.com‘s news article titled: “26 Stocks Moving In Tuesday’s Pre-Market Session” with publication date: May 29, 2018.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company has market cap of $163.89 million. The firm promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. It currently has negative earnings. The Company’s clinical-stage pipeline includes TALICIA , an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S.
Among 8 analysts covering RedHill Biopharma (NASDAQ:RDHL), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma had 15 analyst reports since July 29, 2015 according to SRatingsIntel. TH Capital maintained RedHill Biopharma Ltd. (NASDAQ:RDHL) rating on Wednesday, July 29. TH Capital has “Buy” rating and $31 target. Nomura initiated the stock with “Buy” rating in Tuesday, September 29 report. FBR Capital maintained the stock with “Outperform” rating in Friday, February 24 report. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) has “Buy” rating given on Wednesday, May 9 by H.C. Wainwright. The company was maintained on Tuesday, November 14 by Roth Capital. The company was upgraded on Saturday, August 22 by Zacks. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) has “Buy” rating given on Thursday, June 15 by FBR Capital. The firm has “Buy” rating given on Tuesday, September 29 by Northland Capital. The rating was downgraded by TheStreet to “Hold” on Tuesday, August 25. The rating was maintained by H.C. Wainwright on Thursday, June 15 with “Buy”.
Analysts await RedHill Biopharma Ltd. (NASDAQ:RDHL) to report earnings on July, 24. They expect $-0.47 earnings per share, up 21.67% or $0.13 from last year’s $-0.6 per share. After $-0.50 actual earnings per share reported by RedHill Biopharma Ltd. for the previous quarter, Wall Street now forecasts -6.00% EPS growth.
More news for Cancer Genetics, Inc. (NASDAQ:CGIX) were recently published by: Nasdaq.com, which released: “Cancer Genetics Strengthens Management Team with Appointment of Michael McCartney as Chief Commercial Officer” on June 12, 2018. Seekingalpha.com‘s article titled: “Cancer Genetics’ (CGIX) CEO Jay Roberts on Q1 2018 Results – Earnings Call Transcript” and published on May 15, 2018 is yet another important article.
Among 7 analysts covering Cancer Genetics (NASDAQ:CGIX), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Cancer Genetics had 13 analyst reports since March 11, 2016 according to SRatingsIntel. Aegis Capital maintained Cancer Genetics, Inc. (NASDAQ:CGIX) rating on Tuesday, March 15. Aegis Capital has “Buy” rating and $8 target. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, November 29. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) earned “Buy” rating by H.C. Wainwright on Tuesday, January 16. H.C. Wainwright maintained Cancer Genetics, Inc. (NASDAQ:CGIX) on Tuesday, August 15 with “Buy” rating. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has “Buy” rating given on Thursday, December 7 by Maxim Group. The stock has “Buy” rating by H.C. Wainwright on Thursday, September 21. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has “Buy” rating given on Monday, September 26 by Rodman & Renshaw. The rating was downgraded by Maxim Group to “Hold” on Tuesday, April 3. Janney Capital downgraded the shares of CGIX in report on Friday, March 11 to “Neutral” rating. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, February 6.
Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $30.45 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The companyÂ’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.
Investors sentiment increased to 1.11 in 2018 Q1. Its up 0.20, from 0.91 in 2017Q4. It is positive, as 3 investors sold Cancer Genetics, Inc. shares while 6 reduced holdings. 6 funds opened positions while 4 raised stakes. 2.70 million shares or 2.75% less from 2.78 million shares in 2017Q4 were reported. Dimensional Fund Advsr L P stated it has 19,866 shares. Blackrock invested in 44,920 shares. Renaissance Techs Ltd Liability Company has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). Granahan Inv Mngmt Ma reported 0.03% stake. Spark Investment Mngmt Llc holds 11,600 shares. Northern Corporation reported 32,576 shares. Morgan Stanley holds 0% or 16,169 shares in its portfolio. Natl Bank Of America De invested in 625 shares. Geode Cap reported 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). The Pennsylvania-based Sei Investments Com has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Diker Mgmt Lc reported 0.04% stake. Wells Fargo Communication Mn reported 16,800 shares stake. Jacobs Levy Equity holds 0% or 16,489 shares in its portfolio. Virtu Ltd Limited Liability Company stated it has 29,495 shares. 963,600 are held by Perkins Mgmt Incorporated.